Figure 2

The effects of sTGF-βR on tumor growth according to timing of administration relative to tumor-challenge, animal model, and murine lung cancer cell line. In all graphs, tumor volume was calculated by the formula (π*long axis*short axis*short axis)/6 and displayed as mean volume (mm³). Error bars represent standard error of the mean (SEM). IgG2a (control) and sTGF-βR were administered according to specific schedules. Animals with small (150 mm³), established tumors (Graph A) received IP injections of IgG2a (control) or sTGF-βR, once every 3 days, for a total of 6 doses. Pretreatment animals (Graphs B-F) received IP injections of IgG2a (control) or sTGF-βR two days before tumor cell-inoculation, and once every 3 days thereafter, for a total of 3 doses. (A). AB12 (established tumors), BALB/c animals (n=5). Established AB12 tumors in animals treated with sTGF-βR were significantly smaller than tumors in control animals treated with IgG2a at multiple time points (* = p < 0.05). (B). L1C2 (pretreatment), BALB/c animals (n=5). L1C2 tumors in animals pretreated with sTGF-βR were significantly smaller than tumor in control animals pretreated with IgG2a at multiple time points (* = p < 0.05). (C). TC-1 (pretreatment), C57BL/6 animals (n=5). TC-1 tumors in animals pretreated with sTGF-βR were significantly smaller than tumors in control animals pretreated with IgG2a at one time point (* = p < 0.05). (D). AB-1 (pretreatment), BALB/c animals (n=5). No significant difference in AB-1 tumor size was evident between control animals pretreated with IgG2a and animals pretreated with sTGF-βR (p > 0.05). (E). AB12 (pretreatment), BALB/c animals (n=5). AB12 tumors in animals pretreated with sTGF-βR were significantly larger than tumors in control animals pretreated with IgG2a at multiple time points (* = p < 0.05). (F). AB12 (pretreatment), SCID animals (n=5). No significant difference in AB12 tumor size was evident between control animals that received IgG2a and animals that received sTGF-βR (p > 0.05).